Literature DB >> 18198924

Efficient electrotransfection into canine muscle.

D Pavlin1, N Tozon, G Sersa, A Pogacnik, M Cemazar.   

Abstract

Two different types of electroporation protocols have been developed for efficient electrotransfer of plasmid DNA into skeletal muscle of experimental animals. At first, only low voltage electric pulses have been used, but lately, a combination of high and low voltage pulses has been suggested as more efficient. Up to date, in dogs, this type of electroporation protocol has never been used for muscle targeted plasmid DNA electrotransfection. In this study, we used two different DNA plasmids, one encoding green fluorescent protein and one encoding human interleukin-12. Five different electroporation protocols were evaluated. Three of them featured different combinations of high and low voltage pulses, and two were performed with delivery of low voltage pulses only. Our study shows that combination of 1 high voltage pulse (600 V/cm, 100 mus), followed by 4 low voltage pulses (80 V/cm, 100 ms, 1 Hz) yielded in the same transfection efficiency as the standard trains of low voltage pulses. However, this protocol is performed quicker and, thus, more suitable for potential use in clinical practice. In addition, it yielded in detectable systemic expression of human interleukin-12. Electrotransfer of either of the plasmids was associated with only mild and transitory local side effects, without clinically detectable systemic side effects. The results indicate that electrotransfection is a feasible, effective, and safe method for muscle targeted gene therapy in dogs, which could have potential for clinical applications in veterinary medicine of small animals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18198924     DOI: 10.1177/153303460800700106

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  6 in total

1.  Physiological and histological changes in skeletal muscle following in vivo gene transfer by electroporation.

Authors:  Joseph A Roche; Diana L Ford-Speelman; Lisa W Ru; Allison L Densmore; Renuka Roche; Patrick W Reed; Robert J Bloch
Journal:  Am J Physiol Cell Physiol       Date:  2011-08-10       Impact factor: 4.249

2.  Safety and efficacy of tumor-targeted interleukin 12 gene therapy in treated and non-treated, metastatic lesions.

Authors:  Jeffry Cutrera; Glenn King; Pamela Jones; Kristin Kicenuik; Elias Gumpel; Xueqing Xia; Shulin Li
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

Review 3.  Electroporation advances in large animals.

Authors:  Scott D Reed; Shulin Li
Journal:  Curr Gene Ther       Date:  2009-08       Impact factor: 4.391

4.  Electrogene therapy with interleukin-12 in canine mast cell tumors.

Authors:  Darja Pavlin; Maja Cemazar; Andrej Cör; Gregor Sersa; Azra Pogacnik; Natasa Tozon
Journal:  Radiol Oncol       Date:  2010-09-22       Impact factor: 2.991

5.  Optimizing hyaluronidase dose and plasmid DNA delivery greatly improves gene electrotransfer efficiency in rat skeletal muscle.

Authors:  Thorbjorn Akerstrom; Kenneth Vedel; Josefine Needham; Pernille Hojman; Eftychia Kontou; Ylva Hellsten; Jørgen F P Wojtaszewski
Journal:  Biochem Biophys Rep       Date:  2015-10-22

Review 6.  IL-12 based gene therapy in veterinary medicine.

Authors:  Darja Pavlin; Maja Cemazar; Gregor Sersa; Natasa Tozon
Journal:  J Transl Med       Date:  2012-11-21       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.